Waters Corporation

WAT • Medical - Diagnostics & Research

$449.13

▲ +6.30 (+1.42%)

Precio actual

ResultadosÚltimo reporte: 4 jul 2026

PERFIL EQUILIBRADONeutralConfianza: 70%

Perfil cuantitativo — no constituye una recomendación de inversión.

Perfil cuantitativo — no constituye una recomendación de inversión.Metodología

Tesis del análisis: Perfil mixto. La empresa no es necesariamente mala, pero la valoración, el crecimiento o el balance todavía no justifican una señal más fuerte.

Capitalización

$43.49B

Crecimiento

10.0%

Flujo de caja

5/5

Tendencia

Stable

Evidencia

Márgenes estables o en mejora · 20.3%Flujo de caja libre positivo · 9.07Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.58Liquidez saludable · 1.73

Datos financieros hasta: 4 jul 2026, 12:00 a.m. UTCÚltima actualización de earnings: 4 jul 2026, 12:00 a.m. UTCÚltima actualización del perfil: 13 ago 2026, 12:05 p.m. UTC

Resumen de la compañía

Valoración, calidad, fortaleza financiera, momentum y datos de analistas.

Price$449.13

Change1.42%

Shares Out98.20M

Market Cap$43.49B

Enterprise Value$42.95B

52W Range282.77 - 416.62

Beta1.19

P/E261.76

P/S9.36

P/B2.86

P/FCF109.69

EV/Sales9.25

Price$449.13

Change1.42%

Shares Out98.20M

Market Cap$43.49B

Enterprise Value$42.95B

52W Range282.77 - 416.62

Beta1.19

P/E261.76

P/S9.36

P/B2.86

P/FCF109.69

EV/Sales9.25

EV/EBITDA72.21

EV/FCF108.33

Earnings Yield0.38%

FCF Yield0.91%

Dividend Yield0.00%

Gross Margin57.77%

Oper. Margin28.22%

Profit Margin20.30%

Debt/Eq0.58

Current Ratio1.73

Quick Ratio1.27

Revenue 5Y10.03%

FCF 5Y11.33%

Target$453.50

Target Upside0.97%

Target Median$455.00

Target Range387.00 - 515.00

Volume597.84K

Avg Volume987.73K

EPS Surprise0.39

ADN de inversión

Qué tan fuerte luce esta compañía para inversionistas de largo plazo

de 100

Calidad del negocio

Márgenes, ventaja competitiva, retornos

85/100

Fortaleza financiera

Deuda, caja, estabilidad

87/100

Potencial de crecimiento

Ingresos y expansión

45/100

Atractivo del precio

Barata o cara hoy

31/100

Por qué este puntaje▼

Márgenes estables o en mejora · 20.3%Flujo de caja libre positivo · 9.07Flujo de caja libre consistente · 5/5Nivel de deuda manejable · 0.58Liquidez saludable · 1.73Múltiplo de ganancias caro · 35.17

Analyst view

Analyst sentiment and price target

WAT

Analyst sentiment

Based on 37 analyst votes · 2026-10-20

73/100

Bullish

Hold

Bearish

Precio objetivo

2026-08-13

Bajo

$375.00

Promedio

$420.64

Mediana

$420.00

Alto

$475.00

Resumen de la compañía

IPO: 11/17/1995

Industria: Medical - Diagnostics & Research

P/B i: 2.86

Deuda / Patrimonio i: 0.58

Margen operativo: 28.22%

Margen neto: 20.30%

ROE i: -

ROIC: -

Salud financiera

Puntaje17 / 20

Deuda / Patrimonio: 0.58

Ratio corriente: 1.73

Ratio rápido: 1.27

Estado: Strong

Transacciones internas

Actividad reciente de ejecutivos e insiders

KUEBLER CHRISTOPHER A

Transacción: 08/06/2026

VENTA

Cambio

-3,626

Precio

$136.43

Presentación

08/07/2026

Tipo

VENTA

KUEBLER CHRISTOPHER A

Transacción: 08/06/2026

VENTA

Cambio

-3,626

Precio

$397.94

Presentación

08/07/2026

Tipo

VENTA

Jiang Wei

Transacción: 06/30/2026

COMPRA

Cambio

—

Precio

Not reported

Presentación

07/02/2026

Tipo

COMPRA

Insider	Tipo	Cambio	Precio	Transacción	Presentación
KUEBLER CHRISTOPHER A	VENTA	-3,626	$136.43	08/06/2026	08/07/2026
KUEBLER CHRISTOPHER A	VENTA	-3,626	$397.94	08/06/2026	08/07/2026
Jiang Wei	COMPRA	—	Not reported	06/30/2026	07/02/2026
Knight Heather	COMPRA	—	Not reported	06/30/2026	07/02/2026
Carpio Robert L III	VENTA	-189	$369.18	06/24/2026	06/25/2026
Chaubal Amol	VENTA	-239	$352.21	05/12/2026	05/14/2026
Bennett Jianqing	VENTA	-302	$304.09	04/06/2026	04/07/2026
Knight Heather	COMPRA	—	Not reported	03/31/2026	04/02/2026
Jiang Wei	COMPRA	—	Not reported	03/31/2026	04/02/2026
Jiang Wei	COMPRA	+500	$289.46	03/16/2026	03/18/2026
FEARON RICHARD H	COMPRA	+1,000	$306.34	03/06/2026	03/10/2026
Bennett Jianqing	VENTA	-410	$307.23	03/02/2026	03/03/2026
Chaubal Amol	VENTA	-709	$307.23	03/02/2026	03/03/2026
Batra Udit	VENTA	-3,417	$307.23	03/02/2026	03/03/2026
Ornskov Flemming	COMPRA	+57	$319.44	02/25/2026	02/27/2026
Ornskov Flemming	COMPRA	+336	Not reported	02/25/2026	02/27/2026
BADDOUR LINDA	COMPRA	+57	$319.44	02/25/2026	02/27/2026
BADDOUR LINDA	COMPRA	+23	Not reported	02/25/2026	02/27/2026
Brennan Daniel J.	COMPRA	+57	$319.44	02/25/2026	02/27/2026
Brennan Daniel J.	COMPRA	+23	Not reported	02/25/2026	02/27/2026

Sobre la compañía

Waters Corporation

Waters Corporation is a global leader in specialized measurement, delivering analytical solutions across Asia, the Americas, and Europe. The company operates through two main divisions: Waters and TA. Under its Waters segment, it engineers, manufactures, sells, and provides support for high and ultra-performance liquid chromatography and mass spectrometry (MS) systems. This includes essential consumables like chromatography columns and comprehensive post-warranty service plans. The TA segment focuses on designing, producing, selling, and servicing instruments for thermal analysis, rheometry, and calorimetry. Additionally, Waters develops and supplies sophisticated software that integrates with both its own instruments and those from other manufacturers. The company's advanced MS technology plays a crucial role in various applications, such as drug discovery and development (including clinical trial assessments), analyzing proteins involved in disease processes, ensuring nutritional safety, and conducting environmental testing. Its thermal analysis, rheometry, and calorimetry instruments are vital for assessing the suitability and stability of a wide range of materials, including fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids. These instruments support diverse sectors like industrial manufacturing, consumer goods, healthcare products, and life science research. Waters' extensive client base spans the life sciences, pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental sectors, where its products are instrumental in research and development, quality assurance, and general laboratory operations. Established in 1958, Waters Corporation is headquartered in Milford, Massachusetts.

Fuente - Link

Competidores

DGX DXCM ILMN INCY LH MEDP MTD STE WST ZBH

Tamaño = capitalización · color = línea del gráfico

Rendimiento de peers · 1A

Top performers + empresa seleccionada

Ultimas Noticias

Waters Launches AI Link to Advance AI-Enabled LC-MS Workflows

WAT's AI Link launch and Anthropic collaboration aim to automate LC-MS workflows, streamline lab operations and drive instrument demand.

Zacks Investment Research

Waters Corporation and Quest Diagnostics Help Close Cervical Cancer Screening Gap Bringing Nationwide Access to the Most Comprehensive FDA-Cleared At-Home HPV Screening Option

Expands access to most comprehensive FDA-approved HPV test and at-home self-collection option across Quest's national clinician, health plan, and consumer channels starting in 2027 First and only FDA-approved HPV test that supports all ASCCP Enduring Risk-Based Management Guidelines by providing comprehensive extended genotyping Quest Diagnostics serves half of U.S. physicians and hospitals and one in three American adults each year MILFORD, Mass. and SECAUCUS, N.J.

PRNewsWire

Two stocks poised to benefit from rotation out of AI

Investors looking beyond artificial intelligence (AI) should closely watch two healthcare names – Thermo Fisher Scientific (TMO) and Waters (WAT) – according to Josh Brown. In his latest report, the Ritholtz' chief executive highlighted laboratory equipment suppliers whose improving businesses are attracting buyers as tech stocks face pressure.

Invezz

Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

Accelerates research and development by enabling AI-augmented workflows and automated lab-in-the-loop cycles, already a new and fast-growing source of demand for Waters' instruments and consumables Leverages Waters' unique ability to take an AI-directed experiment from the research bench into development and into Empower™ Software, carrying its audit trail as the molecule moves into downstream, regulated settings Joins Anthropic's Model Hardware Standard (MHS) research program designed to enable AI agents to operate Waters instrument hardware directly and autonomously, cutting instrument integration from weeks to hours Brings Anthropic's Model Context Protocol (MCP) to waters_connect™ Software, enabling scientists to direct Waters instruments through proprietary agents linked to large language models (LLMs), as well as Claude Science MILFORD, Mass., Oct. 13, 2026 /PRNewswire/ -- Waters Corporation (NYSE: WAT) today announced that it has launched Waters AI Link, a software capability that brings Anthropic's Model Context Protocol (MCP) to its informatics platform and has joined Anthropic's Model Hardware Standard (MHS) research program.

PRNewsWire

Here's Why You Should Retain WAT Stock in Your Portfolio for Now

Waters' growth outlook is fueled by strong analytical sciences demand, BD synergies and innovation, even as China weakness and integration risks persist.

Zacks Investment Research

Sorpresas de ganancias

Período	Estimado	Real	Sorpresa
2026-05-05	2.31	2.7	0.39
2026-02-09	4.51	4.53	0.02
2025-11-04	3.21	3.4	0.19
2025-08-04	2.94	2.95	0.01
2025-05-06	2.22	2.25	0.03
2025-02-12	4.03	4.1	0.07
2024-11-01	2.68	2.93	0.25
2024-07-31	2.56	2.63	0.07
2024-05-07	2.1	2.21	0.11
2024-02-06	3.55	3.62	0.07
2023-11-07	2.55	2.84	0.29
2023-08-02	2.59	2.8	0.21